Unicentric Form of Castleman Disease - Surgery Therapy Benefit

Sponsor
Charles University, Czech Republic (Other)
Overall Status
Completed
CT.gov ID
NCT05440305
Collaborator
(none)
20
135.9

Study Details

Study Description

Brief Summary

Observation study on patients with unicentric form of Castleman disease, evaluation of surgical treatment benefit. Observation of surgical treatment strategy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: surgery type/exstirpation/debulking

Study Design

Study Type:
Observational
Actual Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Castleman Disease - Diagnosis and Surgery
Actual Study Start Date :
Jan 1, 2011
Actual Primary Completion Date :
Dec 31, 2021
Actual Study Completion Date :
Apr 30, 2022

Outcome Measures

Primary Outcome Measures

  1. 5 year survival [each 6 months checkup, up to 150 weeks, from date of randomization until the date of first documented progression]

    surgery treatment success

  2. recurence rate [each 6 months checkup, up to 150 weeks, from date of randomization until the date of first documented progression]

    surgery treatment success

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patient with unicentric form of Castleman disease

  • underwent surgery resection

Exclusion Criteria:
  • multilocalised Castleman disease

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Charles University, Czech Republic

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jiri Molacek, Principal investigator, Charles University, Czech Republic
ClinicalTrials.gov Identifier:
NCT05440305
Other Study ID Numbers:
  • 750923
First Posted:
Jun 30, 2022
Last Update Posted:
Jun 30, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jiri Molacek, Principal investigator, Charles University, Czech Republic
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 30, 2022